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Objective: Type 1 diabetes (T1D) develops in distinct stages, before and after disease onset.
Whether the natural course translates into different immunologic patterns is still uncertain. This
study aimed at identifying peripheral immune patterns at key time-points, in T1D children
undergoing remission phase.
Methods: Children with new-onset T1D and healthy age and gender-matched controls were
recruited at a pediatric hospital. Peripheral blood samples were evaluated by flow cytometry at
3 longitudinal time-points: onset (T1), remission phase (T2) and established disease (T3). Cyto-
kine levels were quantified by multiplex assay. Fasting C-peptide, HbA1c, and 25OHD were
also measured.
Results: T1D children (n = 28; 10.0  2.6 years) showed significant differences from controls
in circulating neutrophils, T helper (Th)17 and natural killer (NK) cells, with relevant variations
during disease progression. At onset, neutrophils, NK, Th17 and T cytotoxic (Tc)17 cells were
decreased. As disease progressed, neutrophil counts recovered whereas NK counts remained
low. Th17 and Tc17 cells behavior followed the neutrophil variation pattern. B-cells were low-
est in the remission phase and regulatory T-cells significantly declined after remission. Two
cytokine response profiles were identified. Low cytokine-responders showed higher circulating
fasting C-peptide levels at onset and longer remission periods. C-peptide inversely correlated
with pro-inflammatory and cytotoxic cells.
Conclusions: Our data suggest an association between immune cells, cytokine patterns and
metabolic counterparts. The dynamic changes of circulating immune cells during disease pro-
gression involve key innate and acquired immune cell types. This longitudinal picture of T1D
progression may enable disease staging and patient stratification, essential for individualized
treatment.
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1 | INTRODUCTION
Type 1 diabetes (T1D) is a metabolic disorder in which the interaction
between genetic susceptibility, environmental factors and immuno-
logic mechanisms leads to a selective destruction of pancreatic
insulin-producing beta-cells.1 This chronic and life-debilitating disease
affects a growing number of young children,2 yet its etiology and
pathogenesis are still unresolved. A T effector/T regulatory (Treg) cell
imbalance has been considered, allowing the expansion of cytotoxic
CD8+ T-3 and B-cells,4 as observed in animal models, along with auto-
antibody production. T1D is also related to MHC-gene polymor-
phisms5 implying an involvement of the adaptive immune system.
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Nevertheless, increasing evidence suggests that innate immune cells
and non-specific inflammation also play a critical role in the patho-
genesis of T1D, as shown by studies in pancreatic insulitis and peri-
pancreatic ganglia.6,7
Along the natural history of T1D, periods of immunologic toler-
ance and autoimmune activity occur, probably as a consequence of
antigen determinants spreading, beta-cell proliferation or cytotoxic
T-cell action.8
It is well recognized that in 40% to 71% of children,9,10 T1D
develops in distinct phases, corresponding to different metabolic and
possibly immunological stages.8 After onset, a remission phase or
“honeymoon” may occur, with a partial and transitory restoration of
endogenous insulin production. This natural phenomenon has been
attributed to lower metabolic glucotoxicity, due to action of exoge-
nous insulin and glycaemic improvement. Several authors have
hypothesized that the “honeymoon” is a phase of immunotolerance
in a relapse-remitting disease.8,11
Studies approaching peripheral blood (PB) and target organ are
crucial to identify biomarkers as predictors for early and individual-
ized intervention. Moreover, the dynamics of disease course in
humans requires a thorough investigation to identify an optimal ther-
apeutic window for induction of beta-cell regeneration and restora-
tion of immunotolerance.
Current knowledge of T1D pathogenesis relies mostly on animal
models, which do not fully mirror the human T1D pathology, as
recently documented in a direct comparative study.12 On the other
hand, the risks of presently available techniques to access the pan-
creas in vivo restrain organ studies in humans, and consequently
human data on disease progression are rare.13,14
Circulating immune cells in T1D patients may reflect the events
occurring in the pancreas15 and may predict the occurrence of the
remission phase,16 but prospective longitudinal data are limited.
One study in children with T1D suggested that specific immunolog-
ical signatures are related to disease severity17 and functional
changes in circulating Treg have been reported at different disease
stages.18
Thus, we hypothesize that changes in the profile of PB immune
cell subsets and cytokines may reflect the natural course of T1D in
humans. This study aimed to identify peripheral immune patterns in
T1D children during disease progression, and to determine whether a
link between the inflammatory status and metabolic severity exists.
The longitudinal picture of T1D progression may enable disease stag-
ing and patient stratification, which will allow for individualized
treatment.
2 | METHODS
2.1 | Study population
Children with new-onset T1D were recruited at admission for
18 months in a central pediatric hospital. Inclusion criteria were: age
5 to 17 years old, and <14 days after diagnosis. T1D was defined
according to the ADA criteria,19 with at least one positive autoanti-
body (anti-insulin; Insulinoma-Associated-2; antiglutamic acid
decarboxylase). Children with other autoimmune diseases, allergy or
acute infections were excluded. Controls (age and gender-matched)
were selected from the pediatric endocrinology outpatient clinic,
where they were evaluated due to variants of normal growth and/or
puberty. Initially, 42 patients were recruited, of which 28 completed
the study (Figure 1).
2.2 | Study design
Blood samples were collected at 3 distinct time-points throughout
individual disease development. At disease onset (time-point 1: T1),
samples were collected between 1 and 14 days after diagnosis. At
partial remission (time-point 2: T2) and at “established disease” (time-
point 3: T3), samples were collected according to the value of Insulin
dose adjusted to HbA1c (IDAA1c), used as a surrogate measure of
endogenous insulin production. IDAA1C = HbA1C(%) + (4× insulin
dose [units per kilogram per 24 hours]).20 T2 was collected once the
patient entered partial remission phase (IDAA1C ≤ 9) and T3 was col-
lected once patients entered established disease phase, that is,
IDAA1C > 9.
Control samples were collected simultaneously to T1. Longitudi-
nal data collection occurred in a 2-year time-period. The number of
cases admitted to the hospital during the study period determined
the initial sample size. For study evaluation, only patients with suc-
cessful sample collection in all time-points were considered
(Figure 1).
The study was approved by the hospital's ethics committee and
conducted in accordance with the Declaration of Helsinki. Informed
consent forms were signed.
2.3 | Sample collection
Blood samples for immunophenotyping and cell stimulation were col-
lected in EDTA and heparin tubes, respectively, and processed within
24 hours. For cytokine quantification, sera were obtained by centrifu-
gation after clot retraction, separated in aliquots and stored at −20C
until analysis.
2.4 | Flow cytometry
Multicolor flow cytometry was used for characterization of immune
cell subsets, using a BD FACS Calibur (BD Biosciences, San Jose,
California) equipped with 2 lasers (488 nm air-cooled argon-ion laser,
and 635 nm red diode laser). For characterization of leukocyte and
lymphocyte subpopulations the BD Multitest IMK Kit with Trucount
absolute counting tubes (BD Biosciences) was used, according to
manufacturer's instructions.
For Treg phenotyping, the panel of mAbs included anti-CD3-
FITC (clone SK7, BD Biosciences), anti-CD25 PE (clone BC96, Biole-
gend, California), anti-CD4 PerCPCy5.5 (clone SK3, Biolegend) and
anti-CD127 AlexaFluor647 (clone A019D5, Biolegend) (Additional
information in Figure S1, Supporting Information).21,22
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2.5 | Cell stimulation for intracellular cytokine
evaluation
The expression of IFN-γ and IL17 was used to assess Th1 and Th17
cells. For this, heparinized whole blood samples were stimulated with
PMA (50 ng/mL; Sigma Aldrich, St. Louis, Missouri) and calcium iono-
phore (1 μg/mL, Sigma Aldrich) for 5 hours at 37C in a 5% CO2
atmosphere, in the presence of Brefeldin A (1.0 μg/mL, BD Pharmin-
gen, San Jose, California). For control purposes, unstimulated cells
were incubated in parallel. The protocol was performed according to
the Cytofix-Cytoperm kit (BD Pharmingen) instructions (Additional
information in Figure S2).
2.6 | Serum cytokines quantification by Luminex
technology
Serum cytokines (IL-1β, IL-2, IL-4, IL-6, IL-10, IL-13, IL17-A, IFN-γ,
MCP-1 and TNF-α) were accessed by a multiplex strategy. A 10-plex
Bioplex Human Cytokine Assay kit (Bio-Rad Laboratories, Inc.,
Hercules, California) was used for the quantification, according to
manufacturer recommendations.
2.7 | Indicators of metabolic status
Glycated hemoglobin HbA1C was determined by chromatography
(Variance 2-Biorad, Hercules, California) and fasting C-peptide and
25-OHD were determined by chemiluminescence (Immulite 2000,
Siemens, Germany).
2.8 | Statistical analysis
GraphPad Prism software v.6.01 (GraphPad Software, La Jolla,
California) was applied. Categorical variables were analyzed by
Fisher's exact test or χ2. Normality of distributions was assessed by
D'Agostino & Pearson test. Data normally distributed were presented
as mean  SD, otherwise as median and interquartile range. Paired
groups were analyzed with paired Student's t test or Wilcoxon test.
Unpaired Student's t or Mann-Whitney tests were used to compare
each 2 independent groups. P < .05 was considered significant.
3 | RESULTS
3.1 | Characteristics of the study population
Table 1 summarizes demographic and metabolic data from T1D
patients and controls. The T1D group comprised 28 children (mean
age: 10.0  2.6 years, 46% males). At disease onset (T1), samples
were collected 4  2 days after diagnosis. At partial remission (T2),
average sample collection time was 10746 days after diagnosis, and
at established disease (T3) 398104 days after diagnosis. Remission
phase (T2-T3) duration was on average 279  118 days (Figure 1).
No relevant seasonal clustering was identified.
3.2 | Neutrophils and NK-cells were decreased at
T1D onset with regain of neutrophils but not of NK-
cells
Compared to controls, both neutrophils and NK-cell counts were sig-
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Diagnosis – T1: 4 ± 2 days
T1 – T2: 107 ± 46 days
T2 – T3: 279 ± 118 days
T1 – T3: 398 ± 104 days
FIGURE 1 Study design.
T1D, type 1 diabetes;
T1, time-point 1 (new-onset disease);
T2, time-point 2 (remission phase);
T3, time-point 3 (established disease);
IDAA1C, insulin dose adjusted HbA1C
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P = .0115, respectively) (Figure 2B,D). The frequency of NK-cells was
also significantly lower (P = .0012) (Figure 2C). Upon disease progres-
sion, neutrophils increased, both in absolute counts (T1-T2 P = .1375;
T1-T3 P = .0082; T2-T3 P = .0112) and frequency (T1-T2 P = .0564;
T1-T3 P = .0005; T2-T3 P = .0089). This neutrophil recovery was
most pronounced at the final stage, reaching the control group values
(Figure 2A,B). Similarly, NK-cells significantly increased during disease
progression (T1vsT2 P = .0139; T1vsT3 P = .0188; T2vsT3
P = .9670). However, absolute counts and percentages remained
diminished at T3 (respectively, P = .0307; P = .0789) compared to
controls (Figure 2C,D).
3.3 | B-cells reached their lowest level during the
remission phase
B-cells significantly decreased from T1 to T2, without further
changes, both in absolute number (T1-T2 P = .0002; T1-T3
P = .0006) and frequency (T1-T2 P = .0003; T1-T3 P = .0075)
(Figure 2E,F). No correlation was identified for B-cells, considering
metabolic parameters (C-peptide, HbA1c, and vitamin D) and duration
of disease stages.
3.4 | The regain of pro-inflammatory Th1 and Th17
cells after T1D onset was accompanied by a decline
of regulatory T-cells after remission
Compared to control values, Th1 and Tc1 cell subsets did not show
significant differences in T1D children at any time-point. However, a
significant increase was detected during the disease course (Th1%
T1-T2 P = .0041, T1-T3 P = .0014; Tc1% T1-T2 P = .0032, T1-T3
P = .0004). The rise of these pro-inflammatory cells occurred mainly
in stage T2 (Figure 3A,B). Differently, Th17 and Tc17 cell populations
were significantly decreased, in T1D children compared to controls,
already at disease onset (Th17% P = .0047, Th17 cells/μL P = .0155;
Tc17% P = .0003, Tc17 cells/μL P = .0017). Although there was a sig-
nificant increase during disease progression (Th17% T1-T2 P = .0322;
T1-T3 P = .0207; Tc17% T1-T3 P = .0218), both populations
remained below control levels (Figure 3C,D). Treg frequency and
numbers were not significantly different from controls at any of the
3 time-points. However, Treg significantly decreased in the estab-
lished disease phase (Treg% T2-T3 P = .0016; Treg cells/μL T1-T3
P = .0028; T2-T3 P = .0497) (Figure 3E,F). Addressing the ratios,
Th17/Treg was significantly lower at disease onset, compared to con-
trols (P = .0117). Th1/Treg was not different at any time-point. Along
the disease course, both ratios significantly increased (Th1/Treg
T1-T3 P = .0036; Th17/Treg T1-T3 P = .0118).
3.5 | C-peptide at T1D onset was related to the
immune cell pattern and duration of the remission
phase
At disease onset, C-peptide inversely correlated with absolute counts
of pro-inflammatory and cytotoxic cells, namely T-cells (r = −.395;
P = .042) (Figure 4A), NK-cells (r = −0.486; P = .010) (Figure 4B), Tc1
cells (r = −0.479; P = .011) (Figure 4C) and total IFN-γ-secreting
CD8 T-cells (r = −0.481; P = .011). A positive correlation between
C-peptide at disease onset and remission duration was also identified
(r = 0.381; P = .050). Children with lower C-peptide at onset had
shorter remission phases.
3.6 | Limited impact of vitamin D status at T1D
onset
To address the effect of seasonality, we compared T1D patients with
disease onset from November to April with patients diagnosed from
May to October. Our results revealed no significant differences
regarding vitamin D levels and immune cells and cytokines in the
2 groups. Also, at T1D onset, vitamin D levels did not correlate with
any of the immune parameters evaluated (cell subsets and cytokines).
3.7 | Serum cytokines at disease onset were related
to C-peptide levels and duration of the remission
phase
Regarding cytokine concentrations, no differences were found for
any studied cytokines between T1D children (T1, T2, or T3) and con-
trols; neither significant variation along disease progression was
observed.
However, we identified 2 cytokine patterns within our patients:
low responders (LR), with no detectable anti-inflammatory cytokines
(IL-4, IL-10, IL-13) and no pro-inflammatory TNF-α; high responders
(HR) with at least one of these cytokines detected (IL-4, IL-10, IL-13,
or TNF-α). Consistently, the HR group presented higher levels of other
cytokines such as IL2 (P = .038), IL-6 (P = .002), IFN-γ (P < .001) and
MCP-1 (P = .004) at onset; IL2 (P = .014), IL-17A (P = .022) and IFN-γ
(P = .046) at partial remission and IL1-β (P = .019), IL2 (P = .003), IL-6
(P = .004), IL-17A (P = .035), IFN-γ (P = .002) and MCP-1 (P = .009)
after disease establishment.
LR had both higher circulating fasting C-peptide levels at disease
onset (P = .008) and longer remission periods (P = .005) compared to
HR (Figure 5A,B). There were no differences between LR and HR
regarding immune cell subsets. No correlation between cytokine
levels and age was identified.















Onset fasting C-peptide, ng/mL
(median, IQR)
Patients (n = 28) 10 (3) 14/14 16.8 (3.0) 24/28 9/28 10/28 12.7 (2.4) 0.3 (0.2; 0.6)
Controls (n = 28) 10 (3) 14/14 — — — — — —
Abbreviations: AIA, anti-insulin autoantibody; F, female; GAD, antiglutamic acid decarboxylase autoantibody; IA2, insulinoma-associated-2 autoantibody;
IQR, interquartile range; M, male; SD, standard deviation.
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4 | DISCUSSION
Various models of T1D disease progression have been published,
based mostly on animal studies.12 To the best of our knowledge, this
is the first study which prospectively monitors immune cell subsets
and cytokines in T1D children from disease onset throughout the
remission phase up to disease final establishment.
T1D children differed significantly from healthy controls in circu-
lating neutrophils, Th17 and NK-cells, with relevant variations at
onset, partial remission and disease establishment. In addition, B-cells,
Treg and IFN-γ producing T-cells significantly varied during disease
progression. The natural history of T1D seems to be modulated by
immune parameters, as they correlate with residual insulin
production. Considering the cytokine environment, 2 profiles were
identified in T1D patients, low and high responders, with significantly
different basal C-peptide levels at disease onset as well as distinct
periods of remission.
The neutrophil reduction at disease onset has previously been
described in humans with T1D but was not evident in T2D patients,
suggesting that such a decrease is not due to impaired glycaemic con-
trol.23 The reason for decreased neutrophil counts is most likely tis-
sue sequestration. Accordingly, data on T1D pancreas morphology
have shown neutrophil infiltration in exocrine pancreas at disease
onset.23,24 Recruitment of these innate immune cells to the pancreas
by the pro-inflammatory IL-17 environment is one of the proposed











































































































FIGURE 2 Neutrophils, NK and B-cells
peripheral immune pattern from T1D
onset to established disease.
Percentages and absolute counts of
peripheral neutrophils (A, B), NK (C, D)
and B-cells (E, F) from T1D children and
healthy controls. PB collection at disease
onset (T1), partial remission (T2) and
disease establishment (T3). *P < .05,
**P < .01, ***P < .001 by Mann-
Whitney test (patients vs controls) or
Wilcoxon matched-pairs signed rank test
(comparison within patients in different
time-points)
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IL17-producing cells are involved in both neutrophil recruitment and
activation at inflammatory sites.25 Similar to other autoimmune dis-
eases, significant migration of Th17 cells and neutrophils to the target
organ can play a major role in early disease stages.26
Evidence for Th17 cells in the pancreas27 and pancreatic lymph
nodes,28 as well as the presence of neutrophils in pancreatic tissues
of T1D donors, but not of healthy donors,23 supports the recruitment
of neutrophils into inflammatory areas, leading to pancreatic tissue
damage.7 Circulating neutrophil reduction went along with the early
phase of active, ongoing and specific autoimmune pancreatic beta-
cell destruction.7 In line with this hypothesis, we observed that neu-
trophils positively correlated with the duration of remission phase
(unpublished results).
In our T1D population, neutrophils started to recover at remis-
sion, significantly increasing at established disease. Differently, pro-
longed mild neutropenia has been described, with later resolution,
5 years after diagnosis.23 An explanation for these different results
might be the relapsing-remitting character of T1D disease course. We
speculate that a regain of neutrophils during remission phase results
not only from a reduction of migratory events toward the pancreas,
but also from increased medullary neutrophil differentiation, pro-
moted by Th17 immunity.29 A similar pattern was evident in our study
for both neutrophils and IL17-producing cells in T1D patients, reinfor-
cing that the Th17/neutrophil pathway is primarily involved in the
immunopathology of T1D.7 Reports on circulating levels of IL-17-
producing cells in T1D are controversial, showing either increased30,31
or unchanged levels compared to controls.32 It may be argued that
lower numbers of peripheral IL-17-producing cells reflect increased
recruitment to the target organ and draining lymph nodes that out-
weighs numbers of circulating cells.28 In addition, the synergism
between Th17 and Th1 cells is generally accepted in T1D pathogene-






















































































































FIGURE 3 T-cell differentiation subsets
from T1D onset to established disease.
Peripheral pattern of Th1 (A), Tc1 (B),
Th17 (C), Tc17 (D) and Treg (E, F) from
T1D children and healthy controls. PB
collection at disease onset (T1), partial
remission (T2) and disease establishment
(T3). *P < .05, **P < .01, ***P < .001 by
Mann-Whitney test (patients vs controls)
or Wilcoxon matched-pairs signed rank
test (comparison within patients in
different time-points)
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secreting T-cells in T1D and controls (unpublished observation), con-
firming earlier observations.31
In accordance with previous studies, Treg counts did not differ
between patients and controls.18,33 However, a Treg depletion has
been described in new-onset34 and long-standing T1D.34,35 Differ-
ences in phenotyping strategies used for Treg identification may
explain discrepancies between studies.30 On the other hand, the sig-
nificant decrease in Tregs at T3 may reflect a quantitative impairment
resulting from long-term activation of these cells during the chronic
autoimmune inflammatory process.36 The increase in Th17/Treg ratio
observed during the disease course in our T1D children has been
described before.37 This dynamics highlights again the role of Th17
immunity in T1D,38,39 sustaining the idea that the classic Th1/Th2
paradigm is not sufficient to explain the immunopathogenic events
that lead to autoimmune diabetes.
Though NK frequencies varied in different studies reduced NK
counts have been previously described in T1D children.40 Whether
NKs are disease-controlling or disease-promoting cells in T1D is still
unclear.41 However, the fact that T1D children with higher levels of
NK-cells have shorter remission phases (unpublished observation)
suggests a pathogenic pancreatic involvement of NK-cells in T1D.
Increased circulating cytotoxic cells, namely NK-cells or Tc1 cells,
and a higher cytokine response in those children with lower C-
peptide levels at disease onset reflects a close relation between
immune subsets and metabolic counterparts in T1D children. There-
fore, a link between more severe disease patterns and inflammation-
prone environment is likely to exist.
Cytokines are known to be involved in autoimmune destruction
of beta-cells.42,43 Other groups have attempted to use single cyto-
kines as disease progression markers, but no correlations were found
during the first year of disease.16 Pro-inflammatory cytokines in our
T1D patients were comparable to age-matched healthy controls, simi-
lar to recent data on circulating IL-17 in T1D children and controls
under 15 years of age44 as well as to cytokine and chemokine levels
between T1D patients and brain-dead organ donors.45
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FIGURE 4 Correlation between immune cell populations and fasting
C-peptide at T1D onset. T-cell (A), NK (B) and Tc1 (C) absolute
counts are shown in correlation to fasting C-peptide. P < .05 by
Spearman's rank order correlation
FIGURE 5 Fasting C-peptide levels and remission phase duration in
T1D children with low and high-cytokine responses. Fasting
C-peptide (A) and duration of remission phase (B) were compared
between patients in 2 categories of cytokine response: low
responders (LR) and high responders (HR). **P < .01 by Mann-
Whitney test
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Although cytokines are typically classified as pro- or anti-inflam-
matory, growing evidence suggests that the activity of a given cyto-
kine may be influenced by the timing of response in disease course,
its concentration and the co-existing cytokines in the local milieu.46,47
Indeed, our results demonstrate the importance of the bulk cyto-
kine milieu. The fact that anti-inflammatory cytokines are typically
expressed in conjunction with the pro-inflammatory cytokine TNF-α
indicates that this might be a reactive response to counteract pro-
inflammatory cytokine toxicity. The level of cytokine response possi-
bly influences the remaining beta-cell reservoir in the first stages of
disease as suggested by the observation that children with lower
cytokine levels maintain higher C-peptide at onset and have longer
remission phases.
Data on insulitis might explain the lower peripheral B-cell counts.
In fact, B-cells represent one of the most abundant populations in the
islets after CD8+ T-cells,48,49 being more frequent in the pancreatic
inflammatory infiltrate of late T1D,50 and inversely correlating with
insulin-positivity.48 Recently, a higher prevalence of B-cells was asso-
ciated with a more pronounced hyperimmune infiltration and a youn-
ger age at diagnosis.49 However, in our study, no age-correlation was
found with B-cell counts.
Addressing study design, the purpose of using control samples
was to compare children with and without diabetes. Control samples
were collected simultaneously to T1, in different months along the
2 years of data collection. No further evaluations were performed in
controls, as variations in their immune profile were not expected
(controls did not have any immunologic or inflammatory disorder,
there was no relevant seasonal clustering, and the study's time-span
of circa 1 year, 398 days mean value of monitoring T1D patients,
would not significantly account for age-related variations).
However, a larger sample size, including the evaluation of non-
remitters, would strengthen the external validity in future studies,
and further organ targeted and functional immune subset studies are
required, to correlate the peripheral immune variations with the
events occurring in the pancreas.
In conclusion, immune cell patterns and cytokine environment
are relevant players in the natural course of the disease. The inte-
grated longitudinal picture of T1D progression represents a basis for
disease staging and appropriate patient stratification that will enable
individualized approaches for resetting the immune system.
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